A phase 2 study of this monoclonal antibody failed to meet its primary endpoint at 14 days while signaling potential benefits for high-dose therapy at 28 days. Additional studies may follow.
The recent landmark trial conclusively proved the inflammatory hypothesis of atherothrombosis. But it did a good deal more. Dr. Steven Nissen explains.
This five-minute explainer on the CANTOS, REVEAL and COMPASS studies puts the findings in real-world context for cardiologists.